CG Oncology (NASDAQ:CGON) Hits New 52-Week High on Analyst Upgrade
CG Oncology (NASDAQ:CGON) reached a new 52-week high after HC Wainwright increased its price target from $80 to $100 and reiterated a "buy" rating. The stock traded as high as $69.48, closing near $68.88 on high volume. Analyst sentiment is generally positive with a "Moderate Buy" consensus and a $70.67 target price, and significant institutional investments have occurred despite an insider sale.
CG Oncology stock hits all-time high at 69.41 USD
CG Oncology Inc. stock recently reached an all-time high of $69.41, valuing the biotech company at $5.7 billion. This surge, representing a 342.27% increase over the past year, reflects strong investor confidence despite an InvestingPro analysis suggesting the stock might be overvalued. Analysts maintain a bullish outlook with price targets ranging from $65 to $108, driven by ongoing clinical trials and market potential in cancer therapies.
HC Wainwright Forecasts Strong Price Appreciation for CG Oncology (NASDAQ:CGON) Stock
HC Wainwright has raised its price target for CG Oncology (NASDAQ:CGON) to $100 from $80, maintaining a "buy" rating and suggesting a potential upside of approximately 48%. This update comes as CG Oncology reported better-than-expected Q4 EPS. The company currently holds a "Moderate Buy" consensus rating from analysts, with various institutions and insiders holding stakes in the stock.
A Look At CG Oncology (CGON) Valuation As It Upsizes Its Planned US$550 Million Stock Offering
CG Oncology (CGON) has upsized its planned stock offering to US$550 million, reflecting strong share price momentum and investor focus on its clinical development. While its Price-to-Book ratio of 7.6x makes it appear expensive compared to the broader US biotechs group, a Discounted Cash Flow model suggests the stock is deeply undervalued. The article highlights the contrasting valuation signals and advises investors to review the data, considering key rewards and warning signs before making investment decisions.
CG Oncology stock hits all-time high at 60.01 USD By Investing.com
CG Oncology Inc. stock has reached an all-time high of $60.01, with a market capitalization of $4.88 billion and a 1-year change of 140.69%. This surge indicates strong investor confidence, although InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. The company recently increased its stock offering to $550 million and received raised price targets from analysts following positive developments in its clinical trials.
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON)
Analysts have issued bullish sentiments on two healthcare stocks: Gain Therapeutics (GANX) and CG Oncology, Inc. (CGON). Gain Therapeutics received a Strong Buy consensus with a significant upside potential, while CG Oncology, Inc. also garnered a Strong Buy rating from analysts. Both companies are highlighted for their potential in the healthcare sector.
CG Oncology (NASDAQ:CGON) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded CG Oncology (NASDAQ:CGON) from a "hold" to a "sell" rating. Despite this downgrade, the broader analyst consensus remains a "Moderate Buy" with an average price target of $69, and several other firms have recently raised their price targets. CG Oncology’s shares opened down slightly, but the company recently beat quarterly EPS expectations and has a solid market capitalization.
Vanguard realignment reports 0% ownership in CG Oncology (CGON)
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership of CG Oncology Inc. common stock. This change is attributed to an internal realignment within Vanguard, effective January 12, 2026, where certain subsidiaries will now report their holdings separately. This filing is a procedural reporting update and does not indicate a sale of shares by Vanguard.
UBS raises CG Oncology stock price target to $90 on trial outlook
UBS has increased its price target for CG Oncology Inc. to $90 from $60, maintaining a Buy rating, ahead of anticipated topline data in the first half of 2026 for the company's Phase 3 PIVOT-006 trial. Other analysts, including BofA Securities, Truist Securities, and H.C. Wainwright, have also raised their price targets and reiterated Buy ratings, citing the company's progress towards a Biologics License Application for cretostimogene and strong market position. The company has also amended its stock offering to $550 million.
UBS raises CG Oncology stock price target to $90 on trial outlook
UBS has increased its price target for CG Oncology Inc. (NASDAQ:CGON) to $90 from $60, maintaining a Buy rating, ahead of crucial Phase 3 trial data expected in the first half of 2026. The stock has seen a 148% surge over the past year, trading near its 52-week high. Other analysts like BofA Securities, Truist Securities, and H.C. Wainwright have also raised their price targets, reflecting a positive outlook on the company's financial and strategic advancements, including an increased stock offering and progress towards a Biologics License Application.
Kynam Capital Sells $43.8M in CG Oncology Shares, Reduces Stake to 2.51%
Kynam Capital Management sold 1,059,375 shares of CG Oncology in Q4, reducing its stake to 2.51% of its reportable AUM. This sale, valued at an estimated $43.84 million, reflects the fund's decision to manage exposure after CG Oncology shares surged over 135% in the past year. Despite the reduction, CG Oncology's future performance is closely linked to upcoming clinical trial results for its bladder cancer therapeutic.
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON)
Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with a $72.00 price target. Analyst Alec Stranahan, who has a 5.0% average return and 49.85% success rate, made the recommendation. CG Oncology reported $2.32 million in quarterly revenue and a GAAP net loss of $41.31 million for the quarter ending December 31.
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday
CG Oncology (NASDAQ:CGON) is expected to release its Q4 2025 earnings before market open on Friday, March 27th, with analysts forecasting an EPS of ($0.61). The company's shares opened at $65.86, and it holds a "Moderate Buy" consensus rating from analysts with an average price target of $69.00. Insider selling by Director James Mulay and significant institutional investor activity were also noted.
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON)
Analysts from Truist Financial have issued bullish sentiments on several healthcare stocks, including Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON), and Adicet Bio (ACET). Protagonist Therapeutics and CG Oncology both received "Strong Buy" consensus ratings with significant upside potential, while Adicet Bio also garnered a "Strong Buy" with a substantial potential upside of over 500%.
CG Oncology (NASDAQ: CGON) director sells 1,964 shares after option exercises
CG Oncology director James Mulay exercised stock options for 1,964 shares of Common Stock and subsequently sold the same number of shares in pre-planned trades. These transactions included exercising options at $3.72 and $12.59 per share, followed by selling the shares at $63.50 per share. The sales were conducted under a Rule 10b5-1 trading plan adopted on June 6, 2025, indicating that the trades were scheduled in advance.
CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares
CG Oncology (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the company's stock on March 16th for $124,714. This follows a previous sale of 11,145 shares in January. The company's stock is trading near its 12-month high with a market cap of $5.8 billion, and analysts hold a "Moderate Buy" consensus.
CG Oncology, Inc. $CGON Stake Increased by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 152.1% in the third quarter, bringing its total holdings to 26,040 shares valued at $1,049,000. Other institutional investors like Vanguard Group Inc., Wellington Management Group LLP, Alliancebernstein L.P., Bank of America Corp DE, and Franklin Resources Inc. also modified their holdings in the company. CG Oncology shares opened at $65.90 on Tuesday, reporting a market cap of $5.56 billion, and analysts predict a consensus target price of $69.00 with a "Moderate Buy" rating.
CG Oncology, Inc. $CGON Stake Lessened by Cinctive Capital Management LP
Cinctive Capital Management LP significantly reduced its stake in CG Oncology, Inc. (NASDAQ:CGON) by 61.6% during the third quarter, now owning 32,558 shares valued at $1,311,000. Other institutional investors like PNC Financial Services Group Inc., CWM LLC, and Swiss National Bank either increased or bought new positions in the company. Market analysts have a "Moderate Buy" consensus rating for CG Oncology with an average target price of $69.00.
Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON
Boothbay Fund Management LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 67.9% in the third quarter, bringing its total holdings to 94,479 shares worth $3.81 million. Other institutional investors like Vanguard Group Inc. and Wellington Management Group LLP also boosted their positions. Analyst ratings for CG Oncology are predominantly "Buy" or "Outperform," with a consensus price target of $69.00.
CG Oncology (NASDAQ:CGON) Reaches New 52-Week High - Should You Buy?
CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $65.71, trading significantly above its moving averages, supported by strong analyst ratings including a $93 target from Morgan Stanley. The clinical-stage biopharmaceutical company reported better-than-expected Q4 EPS and has seen notable insider and institutional investment activity. Despite a director's share sale, major funds like Seven Fleet Capital Management and T. Rowe Price have established substantial stakes, reflecting confidence in the company's future.
ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON
ArrowMark Colorado Holdings LLC reduced its stake in CG Oncology by 12.2% in the third quarter, now owning 257,230 shares valued at approximately $10.36 million. Despite this, other institutional investors like Vanguard Group Inc. significantly increased their holdings. CG Oncology generally receives positive sentiment from Wall Street, with an average rating of "Moderate Buy" and a price target of $69.00, following an earnings beat and strong market performance.
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
CG Oncology (CGON) recently expanded its at-the-market stock offering to US$550 million to fund its Biologics License Application for cretostimogene, a bladder cancer therapy. This move, alongside positive analyst updates, highlights the company's clinical momentum for its lead candidate. However, investors face potential dilution risks given the company's current low revenue and significant annual losses, balancing clinical progress with financial considerations.
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts
CG Oncology has expanded its at-the-market stock offering to US$550 million to support its Biologics License Application for cretostimogene, a bladder cancer therapy candidate. This financing, alongside positive analyst views and clinical progress, shapes the investment narrative, focusing on clinical milestones and BLA advancement. While the capital addresses funding concerns, it also raises the prospect of dilution given the company's current low revenue and significant annual losses.
Mangrove Partners IM LLC Increases Stock Position in CG Oncology, Inc. $CGON
Mangrove Partners IM LLC increased its stake in CG Oncology (NASDAQ: CGON) by 21.0% in the third quarter, now holding 671,692 shares valued at $27.06 million. Other institutional investors like Wellington Management, Bank of America, Candriam S.C.A., Vanguard Group, and Millennium Management also significantly grew their positions in the company. Analysts maintain a "Moderate Buy" rating with an average price target of $69.00 for CG Oncology, which recently reported better-than-expected Q4 EPS.
CG Oncology (NASDAQ: CGON) CEO net exercises options and increases share stake
CG Oncology's CEO, Arthur Kuan, recently exercised employee stock options to increase his stake in the company. He acquired 62,765 shares through a net exercise, with 1,847 shares withheld to cover obligations, and now directly holds 198,916 shares. This transaction does not represent an open-market sale but rather an exercise of previously granted options.
Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON
Rosalind Advisors Inc. significantly increased its stake in CG Oncology (NASDAQ:CGON) by 55.5%, now holding 300,000 shares valued at $12.08 million, making it their 10th-largest position. Other institutional investors also built positions, with Vanguard now owning approximately 6.58 million shares and Candriam holding about 1.04 million shares, bringing total institutional ownership to 26.56%. Analysts have a "Moderate Buy" consensus rating for CGON, with an average price target of $69.00.
Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge?
CG Oncology has seen a 143% surge in its share price over the past year, driven by interest in cancer-focused biotech. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 79.2% with an estimated intrinsic value of $303.36 per share, despite its current P/B ratio being higher than the industry average. The company is a late-stage clinical biopharmaceutical company developing treatment for bladder cancer and exhibits high growth potential.
CG Oncology stock rallies nearly 32% in a week: Here is why
The article discusses the significant rally of CG Oncology stock, which has increased by nearly 32% within a week. It aims to explain the reasons behind this rapid stock appreciation, indicating potential positive developments or market sentiment affecting the company.
CG Oncology stock hits all-time high at 63.9 USD
CG Oncology Inc. has reached an all-time high stock price of $63.90, reflecting a 139.33% growth over the past year. Despite analysts setting price targets as high as $108 and strategic moves like increasing its stock offering to $550 million, InvestingPro data suggests the stock might be overvalued. Several financial firms have raised their price targets for CG Oncology, maintaining positive ratings due to advancements in its Biologics License Application and upcoming trial results.
CG Oncology (CGON) Valuation Check After Strong Recent Share Price Momentum
CG Oncology (CGON) has experienced strong stock momentum, with double-digit gains over the past few months, driven by its oncolytic immunotherapy platform. The company's Price-to-Book ratio of 7x appears cheap compared to direct peers but expensive against the broader US Biotech industry, suggesting a premium for its clinical programs despite being loss-making. A discounted cash flow model, however, indicates the shares may be heavily undervalued at $62.80 compared to an estimated future cash flow value of $301.03.
CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026
CG Oncology (NASDAQ: CGON) discussed clinical data, ongoing trials, and launch preparations for its intravesical therapy, cretostimogene ("Credo"), at a recent conference. Key highlights include a 75.5% complete response rate in the BOND-003 Cohort C for BCG-unresponsive CIS patients, with a 12-month CR of 46.4%. The company aims to file a Biologics License Application (BLA) for the high-risk indication in 2026 and an intermediate-risk filing in 2027, emphasizing Credo's durability and favorable safety profile.
JPMorgan Chase & Co. Has $9.18 Million Stock Holdings in CG Oncology, Inc. $CGON
JPMorgan Chase & Co. significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 321.3% in the third quarter, now holding 227,879 shares valued at approximately $9.18 million. This represents about 0.30% of the company's stock. CG Oncology, a clinical-stage biopharmaceutical company focused on solid tumor immunotherapies, beat its quarterly EPS estimates and has a "Moderate Buy" consensus analyst rating with a $69 target price.
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
H.C. Wainwright increased its price target for CG Oncology, Inc. (CGON) to $80 from $75 and maintained a Buy rating, citing progress in the company's biologics application for cretostimogene and expansion into earlier treatment settings. A key 2026 catalyst is the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC. Despite a large EPS miss, the company exceeded revenue estimates and anticipates topline data from PIVOT-006 soon, aiming to establish a new standard in treatment.
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
H.C. Wainwright increased its price target for CG Oncology, Inc. (CGON) to $80 from $75 while maintaining a Buy rating, citing the company's progress with its biologics application for cretostimogene and its expansion into earlier treatment settings. A key catalyst for 2026 is the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC. The company reported better-than-expected FY25 revenue and expects to release topline data from the PIVOT-006 trial soon, aiming to establish a new standard in intermediate-risk NMIBC.
Stock Traders Buy High Volume of Call Options on CG Oncology (NASDAQ:CGON)
Stock traders recently showed unusually high bullish options activity for CG Oncology (NASDAQ:CGON), purchasing 30,105 call options, a 3,313% increase over average. This surge coincides with growing institutional interest and positive analyst ratings, although a director recently sold shares. CG Oncology, a clinical-stage biopharmaceutical company, reported better-than-expected quarterly earnings.
Rafferty Asset Management LLC Lowers Stock Position in CG Oncology, Inc. $CGON
Rafferty Asset Management LLC decreased its stake in CG Oncology, Inc. by 23.1% in the third quarter, while other institutional investors like Millennium Management increased their holdings significantly. Despite this reduction from one firm, institutional ownership remains strong at 26.56%. Analysts generally maintain a "Moderate Buy" rating for CG Oncology, with an average price target of $69.00, and several firms recently raised their price objectives for the stock.
CG Oncology, Inc. $CGON Stock Holdings Trimmed by TD Asset Management Inc
TD Asset Management Inc. reduced its stake in CG Oncology Inc. by 25.8% in Q3, selling 52,696 shares and retaining 151,176 shares valued at approximately $6.09 million. While TD Asset Management trimmed its holdings, other institutions such as Millennium Management LLC, UBS AM, and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased their positions in the company. An insider, Director James Mulay, also sold 11,145 shares for about $584,778. The stock has a "Moderate Buy" consensus rating with a $69 price target.
CG Oncology (NASDAQ:CGON) Sets New 12-Month High - Time to Buy?
CG Oncology (NASDAQ:CGON) recently hit a new 52-week high of $60.69, supported by strong trading volume and multiple analyst price target increases, leading to a "Moderate Buy" consensus rating. The clinical-stage biopharma, despite being unprofitable, surpassed its quarterly EPS estimates and reported $2.32 million in revenue. Institutional investors hold a significant portion of the company, and its stock has shown positive price performance with increasing moving averages.
CG Oncology stock hits all-time high at 60.01 USD
CG Oncology Inc. has reached an all-time high stock price of $60.01 USD, reflecting strong investor confidence and a 140.69% increase over the past year. The company has amended its stock offering to $550 million for financial bolstering, and several firms have raised their price targets due to progress in its Biologics License Application and accelerated clinical trial timelines. Despite the surge, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value.
The Bull Case For CG Oncology (CGON) Could Change Following Surging Revenue And Deeper 2025 Losses – Learn Why
CG Oncology (CGON) reported a significant increase in revenue to US$4.04 million for 2025, but also saw its net loss widen to US$161 million. The company's investment narrative heavily relies on the success of its Phase 3 trials for cretostimogene in bladder cancer, with current commercial traction being minimal. Despite recent share price gains, the deeper losses highlight concerns about cash burn and funding needs, while some retail investors see substantial upside.
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
CG Oncology (CGON) has gained investor attention due to accelerated timelines for its bladder cancer trials and an extended cash runway into 2029. While the stock trades at a 37% discount to analyst targets and an 80% intrinsic discount according to a DCF model, its Price-to-Book ratio of 6.6x suggests it's valued above broader industry averages but below some close peers. The company's current net loss of $160.995 million highlights the speculative nature of its valuation, which heavily relies on future trial success and cash generation.
CGON Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of CG Oncology, Inc. (CGON) for fiscal year 2025, including income statements, balance sheets, and cash flow statements, derived from SEC filings. While the company saw a significant revenue surge of 254.7% to $4.0M, it remains unprofitable with a net income of -$161.0M and a low earnings quality ratio of 0.82x, suggesting accrual-driven earnings. Despite strong growth and liquidity, CGON has a weak Piotroski F-Score of 2/9 and an estimated cash runway of only 3 months.
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
LifeSci Capital analyst Sam Slutsky has reiterated a Buy rating for CG Oncology with a $108.00 price target, citing the differentiation of the PIVOT-006 Phase 3 trial and upcoming clinical and regulatory catalysts in 2026. The analyst highlighted PIVOT-006's design for intermediate-risk NMIBC and the broad patient population it targets, along with anticipated Phase 2 combination data for high-risk NMIBC and the ongoing BLA for cretostimogene. These factors, alongside a solid financial position, support a favorable risk-reward outlook for the company.
Vanguard Group Inc. Has $264.93 Million Stock Position in CG Oncology, Inc. $CGON
Vanguard Group Inc. increased its stake in CG Oncology, Inc. by 11.4%, bringing its total holdings to 6,577,281 shares valued at $264.93 million. Analysts maintain a "Moderate Buy" rating for CGON, with an average target price of $69.00 and recent positive price targets from firms like Morgan Stanley and Goldman Sachs. The company recently beat EPS estimates and has a market capitalization of $4.74 billion, with institutional investors holding 26.56% of the stock.
CG Oncology lines up 2026 NMIBC trial readouts with $903M cash
CG Oncology (NASDAQ: CGON) reported its 2025 year-end financial results, highlighting a cash position of approximately $903.0 million, expected to fund operations into the first half of 2029. The company anticipates key clinical milestones in the first half of 2026, including topline data from its Phase 3 PIVOT-006 trial and initial results from the CORE-008 Cohort CX combination trial for Non-Muscle Invasive Bladder Cancer (NMIBC). Despite a wider net loss of $161.0 million in 2025 due to increased R&D and G&A expenses, the market reacted positively to the news.
The Bull Case For CG Oncology (CGON) Could Change Following Surging Revenue And Deeper 2025 Losses – Learn Why
CG Oncology (CGON) recently reported full-year 2025 results showing a significant increase in revenue to US$4.04 million, but also a widening net loss to US$161 million. This combination highlights the company's substantial investment in its business, with early commercial progress overshadowed by mounting losses. The investment narrative largely depends on the success of its Phase 3 programs for non-muscle invasive bladder cancer and subsequent regulatory decisions, as current stock price gains contrast with increased cash burn and funding risks.
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of "Moderate Buy" by Brokerages
CG Oncology, Inc. (NASDAQ:CGON) has received a "Moderate Buy" consensus recommendation from fourteen brokerages, with an average 12-month target price of $69.00. Several analysts recently upgraded their price targets for CGON, reflecting positive sentiment. The company reported a Q4 EPS of ($0.51), beating estimates, and insiders own 7.4% of the stock, while institutions hold 26.56%.
The Bull Case For CG Oncology (CGON) Could Change Following Surging Revenue And Deeper 2025 Losses – Learn Why
CG Oncology, Inc. reported increased revenue in 2025 but also a widened net loss, reaching US$161 million, indicating significant investment in its business model. The company's investment narrative heavily relies on the success of its cretostimogene Phase 3 programs for bladder cancer, with ongoing financial losses sharpening the focus on cash burn and future funding needs. Despite recent share price gains, the high reliance on clinical trial readouts for future viability makes the stock's investment case dependent on successful regulatory outcomes rather than current commercial traction.
According to the latest financial data from CG Oncology Inc., the company currently holds a total of $903 millions in cash, cash equivalents, and marketable securities.
CG Oncology Inc. has reported $903 million in cash, cash equivalents, and marketable securities. This significant financial reserve is projected to fund the company's operations through the first half of 2029. The data highlights CG Oncology's current fiscal strength and operational runway.
CG Oncology (NASDAQ:CGON) Trading Up 5.6% Following Strong Earnings
CG Oncology (NASDAQ:CGON) saw its stock price rise by 5.6% after reporting stronger-than-expected earnings, with EPS beating consensus estimates. Despite light trading volume, analysts generally maintain a "Moderate Buy" rating with an average price target of $68.58. Insider selling by Director James Mulay was noted, while institutional investors show significant ownership in the company.
